Cellular Immunotherapy Market Size, Trends, Analysis, and Outlook By Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others), By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others),

Cellular Immunotherapy Market Size, Trends, Analysis, and Outlook By Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others), By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others), By End-User (Hospitals, Cancer Institutes, Others), by Region, Country, Segment, and Companies, 2024-2030

The global Cellular Immunotherapy market size is poised to register 18.62% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Cellular Immunotherapy market across By Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others), By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others), By End-User (Hospitals, Cancer Institutes, Others).

The Cellular Immunotherapy Market is experiencing remarkable growth and innovation in 2024 and beyond, fueled by advancements in cancer immunotherapy, adoptive cell therapy, and engineered cell-based therapies designed to harness the power of the immune system to recognize, target, and eliminate cancer cells or infectious pathogens for the treatment of hematologic malignancies, solid tumors, and viral diseases that are refractory to conventional therapies, chemotherapy, or radiation therapy. Cellular immunotherapy encompasses a diverse array of therapeutic approaches, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) therapy, and natural killer (NK) cell therapy, as well as dendritic cell vaccines, tumor-infiltrating lymphocytes (TILs), and cytokine-induced killer (CIK) cells, which are engineered or expanded ex vivo from patient-derived cells, donor cells, or immune cells obtained from allogeneic sources, then reinfused back into patients to enhance immune responses, overcome immune evasion mechanisms, or induce durable antitumor effects in patients with advanced cancers or infectious diseases. Key trends include the development of off-the-shelf, "universal" cell therapies, allogeneic cell products, and gene-edited cell lines that offer scalability, cost-effectiveness, and broad applicability across patient populations, as well as the integration of multi-modal approaches, combination therapies, and personalized treatment strategies that combine cellular immunotherapies with targeted therapies, checkpoint inhibitors, or immune-modulating agents to overcome resistance mechanisms, enhance efficacy, and improve clinical outcomes in cancer patients. Additionally, there is a growing emphasis on manufacturing scalability, process automation, and supply chain logistics that ensure timely production, distribution, and delivery of cellular immunotherapy products to patients, as well as a growing focus on regulatory approval pathways, reimbursement policies, and market access considerations that govern the development, commercialization, and adoption of cellular immunotherapies in healthcare systems, payer networks, and clinical practice guidelines worldwide, fostering innovation, collaboration, and investment in the field of cellular immunotherapy and cancer immunology.

Cellular Immunotherapy Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Cellular Immunotherapy market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Cellular Immunotherapy survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Cellular Immunotherapy industry.

Key market trends defining the global Cellular Immunotherapy demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Cellular Immunotherapy Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Cellular Immunotherapy industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Cellular Immunotherapy companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Cellular Immunotherapy industry

Leading Cellular Immunotherapy companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Cellular Immunotherapy companies.

Cellular Immunotherapy Market Study- Strategic Analysis Review

The Cellular Immunotherapy market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

• Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.
• Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.
• Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.
• Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Cellular Immunotherapy Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Cellular Immunotherapy industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Cellular Immunotherapy Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Cellular Immunotherapy Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Cellular Immunotherapy market segments. Similarly, Strong end-user demand is encouraging Canadian Cellular Immunotherapy companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Cellular Immunotherapy market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Cellular Immunotherapy Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Cellular Immunotherapy industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Cellular Immunotherapy market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Cellular Immunotherapy Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Cellular Immunotherapy in Asia Pacific. In particular, China, India, and South East Asian Cellular Immunotherapy markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Cellular Immunotherapy Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Cellular Immunotherapy Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Cellular Immunotherapy market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Cellular Immunotherapy.

Cellular Immunotherapy Market Company Profiles

The global Cellular Immunotherapy market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Adicet Bio Inc, AstraZeneca, Bristol-Myers Squibb Company, Celyad, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc (Kite Pharma), GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc

Recent Cellular Immunotherapy Market Developments

The global Cellular Immunotherapy market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Cellular Immunotherapy Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

• Pricing Analysis
• Value Chain Analysis
• SWOT Profile
• Market Dynamics- Trends, Drivers, Challenges
• Porter’s Five Forces Analysis
• Macroeconomic Impact Analysis
• Case Scenarios- Low, Base, High

Market Segmentation:

By Therapy Type

CAR T Cell Therapy

Dendritic Cell Therapy

NK Cell Therapy

TIL Therapy

Others

By Indication

B-cell Malignancies

Prostate Cancer

Liver Cancer

Renal Cell Carcinoma

Others

By End User

Hospitals

Cancer Institutes

Others

Geographical Segmentation:

• North America (3 markets)
• Europe (6 markets)
• Asia Pacific (6 markets)
• Latin America (3 markets)
• Middle East Africa (5 markets)

Companies

Adicet Bio Inc

AstraZeneca

Bristol-Myers Squibb Company

Celyad

Dendreon Pharmaceuticals LLC

F. Hoffmann-La Roche Ltd

Gilead Sciences Inc (Kite Pharma)

GlaxoSmithKline plc

Johnson & Johnson

Merck KGaA

Novartis AG

Pfizer Inc

Formats Available: Excel, PDF, and PPT